In response to inquiries from analysts, Jiangxi Fushine Pharmaceutical Co.,Ltd. has detailed its forward-looking strategic plan.

The company's pharmaceutical manufacturing operations will serve as its foundational business, concentrating on high-value-added active pharmaceutical ingredients (APIs). The strategy involves deepening its expertise, solidifying, and expanding its dominant position within its established pharmaceutical sectors.

Concurrently, its new energy lithium battery electrolyte additives business aims to establish a comprehensive one-stop raw material supply platform. This initiative is designed to offer customers a broader product portfolio and more reliable supply chain security.

For its bio-manufactured microbial protein segment, the company will adopt a dual-engine approach targeting both business and consumer markets. On the business-to-business (B2B) front, it will supply microbial protein raw materials and integrated food solutions to downstream food enterprises. For the consumer (B2C) market, expansion will be pursued through its proprietary brands and co-branding partnerships.

By fostering the synergistic development of these three core business areas, the company is committed to evolving into a leading enterprise dedicated to safeguarding both the global environment and human health.